Aripiprazole Tablets USP
Product Mix-Up: A bottle containing Voriconazole Tablets 50 mg was labelled and distributed as Aripiprazole Tablets USP 30 mg.
Yes — there is an active recall. 7 ongoing FDA recalls mention Aripiprazole (29 total). Check the affected lots below.
Most common reason: cGMP deviation (10 of these recalls)
Recalls are matched by product description. A recall usually affects specific lots, not every package of Aripiprazole. “Active” means an FDA recall is still ongoing; “closed” means it was terminated or completed. Checked against openFDA on Oct 10, 2026.
Product Mix-Up: A bottle containing Voriconazole Tablets 50 mg was labelled and distributed as Aripiprazole Tablets USP 30 mg.
Superpotent drug
Cross Contamination with Other Products
Cross Contamination with Other Products
Cross Contamination with Other Products
Cross Contamination with Other Products
cGMP Deviations
Out of specification (OOS) for Spectroscopic Identification test by IR.
CGMP Deviations: recalling drug products following an FDA inspection.
CGMP Deviations: recalling drug products following an FDA inspection.
CGMP Deviations: recalling drug products following an FDA inspection.
CGMP Deviations: recalling drug products following an FDA inspection.
CGMP Deviations: recalling drug products following an FDA inspection.
CGMP Deviations: recalling drug products following an FDA inspection.
Failed dissolution specifications: OOS for dissolution at the 12-month stability time point.
CGMP Deviations: Products were exposed to temperatures outside of the products labeled storage conditions.
Failed Dissolution Specifications: Out of specification for dissolution.
FAILED DISSOLUTION SPECIFICATIONS: Possibility of out-of-specification (OOS) dissolution limits for the remaining shelf life of the Aripiprazole Tablets
Failed Dissolution Specifications: Out of specification for dissolution.
Labeling: Label mix up: Bottles labeled as aripiprazole 2 mg, 30 count had aripiprazole 5 mg tablets, 100 count.
Labeling Not Elsewhere Classified: Physician sample kits/cartons of treatNOW Abilify are mislabeled. Product name is misspelled, storage instructions are missing and contents of kits may be incorrectly labeled on the outer packaging of the co-packaged kit.
Labeling Not Elsewhere Classified: Physician sample kits/cartons of treatNOW Abilify are mislabeled. Product name is misspelled, storage instructions are missing and contents of kits may be incorrectly labeled on the outer packaging of the co-packaged kit.
CGMP Deviations: lot made with active pharmaceutical ingredient that did not meet all its intended specifications.
CGMP Deviations: lot made with active pharmaceutical ingredient that did not meet all its intended specifications.
Superpotent Drug; out of specification results for assay (manufacturer)
Free recall alerts
Tell us what you take. When FDA posts a recall announcement or classifies a recall for one of your medications, we email you in plain English, with what to check. No account needed.